DOERBIO杭州道尔生物科技有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia 2024-09-30 15:00
Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia 2024-07-05 15:56
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA 2023-08-01 17:08
Doer Biologics Announces License Agreement with BioNTech 2023-07-11 11:49
Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer 2022-12-16 09:00
1